AU2011256989B2 - 8-hydroxy-quinoline derivatives - Google Patents

8-hydroxy-quinoline derivatives Download PDF

Info

Publication number
AU2011256989B2
AU2011256989B2 AU2011256989A AU2011256989A AU2011256989B2 AU 2011256989 B2 AU2011256989 B2 AU 2011256989B2 AU 2011256989 A AU2011256989 A AU 2011256989A AU 2011256989 A AU2011256989 A AU 2011256989A AU 2011256989 B2 AU2011256989 B2 AU 2011256989B2
Authority
AU
Australia
Prior art keywords
group
methyl
trifluoromethyl
nitro
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011256989A
Other languages
English (en)
Other versions
AU2011256989A1 (en
Inventor
Liliana Feher
Mario Gyuris
Ivan Kanizsai
Ramona Madacsi
Bela Ozsvari
Laszlo Puskas
Csaba Szabo
Gabor Tamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
"AVIDIN" KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT
UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG
Original Assignee
UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG
Avidin Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG, Avidin Kft filed Critical UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG
Publication of AU2011256989A1 publication Critical patent/AU2011256989A1/en
Application granted granted Critical
Publication of AU2011256989B2 publication Critical patent/AU2011256989B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AU2011256989A 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives Ceased AU2011256989B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1000243 2010-05-06
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (2)

Publication Number Publication Date
AU2011256989A1 AU2011256989A1 (en) 2013-01-10
AU2011256989B2 true AU2011256989B2 (en) 2014-08-21

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011256989A Ceased AU2011256989B2 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Country Status (21)

Country Link
US (1) US8871937B2 (cg-RX-API-DMAC10.html)
EP (1) EP2566849B1 (cg-RX-API-DMAC10.html)
JP (1) JP5812541B2 (cg-RX-API-DMAC10.html)
KR (1) KR101837974B1 (cg-RX-API-DMAC10.html)
CN (1) CN102985407B (cg-RX-API-DMAC10.html)
AU (1) AU2011256989B2 (cg-RX-API-DMAC10.html)
CA (1) CA2798419C (cg-RX-API-DMAC10.html)
CY (1) CY1122426T1 (cg-RX-API-DMAC10.html)
DK (1) DK2566849T3 (cg-RX-API-DMAC10.html)
EA (1) EA021026B1 (cg-RX-API-DMAC10.html)
ES (1) ES2761832T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20192278T1 (cg-RX-API-DMAC10.html)
HU (2) HUP1000243A2 (cg-RX-API-DMAC10.html)
MX (1) MX337999B (cg-RX-API-DMAC10.html)
NZ (1) NZ603967A (cg-RX-API-DMAC10.html)
PL (1) PL2566849T3 (cg-RX-API-DMAC10.html)
PT (1) PT2566849T (cg-RX-API-DMAC10.html)
RS (1) RS59678B1 (cg-RX-API-DMAC10.html)
SI (1) SI2566849T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900710T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011148208A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) * 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
US10624881B2 (en) * 2015-10-12 2020-04-21 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟（胺）基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116092A1 (en) * 2007-03-20 2008-09-25 Brandeis University Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
US20090088420A1 (en) * 2007-04-12 2009-04-02 University Of Southern California Compounds with hiv-1 integrase inhibitory activity and use thereof as anti-hiv/aids therapeutics
WO2009151972A1 (en) * 2008-05-28 2009-12-17 , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015179A1 (en) 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CA2319131A1 (en) 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
US6521617B2 (en) 2000-10-13 2003-02-18 The Johns Hopkins University Treatment of apoptotic cell death
AU2002239595A1 (en) 2000-12-15 2002-06-24 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JP4435563B2 (ja) 2001-07-10 2010-03-17 バイオジェン アイデック インク アポトーシスプロセスの阻害および細胞性能の改善
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
KR20040096571A (ko) 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1633362B1 (en) 2003-05-28 2012-09-26 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
JP5162465B2 (ja) 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
EP2079699A1 (en) * 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
EP2148944A1 (en) 2007-05-25 2010-02-03 Burnham Institute for Medical Research Inhibitors of thapsigargin-induced cell death
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
KR20130027080A (ko) * 2010-01-06 2013-03-14 에리코, 조셉, 피. 표적화된 약물 개발 방법 및 조성물
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116092A1 (en) * 2007-03-20 2008-09-25 Brandeis University Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
US20090088420A1 (en) * 2007-04-12 2009-04-02 University Of Southern California Compounds with hiv-1 integrase inhibitory activity and use thereof as anti-hiv/aids therapeutics
WO2009151972A1 (en) * 2008-05-28 2009-12-17 , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Acharya, J. N., et al, Journal of the Indian Chemical Society, 1976, 53(2), 172-3 *
Brozic, P., et al, Molecular and Cellular Endocrinology, 2009, 301(1-2), 245-50 *
McLean, L. R., et al, Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6717-20 *
Mueller, N. H., et al, Antimicrobial Agents and Chemotherapy, 2008, 52(9), 3385-93 *
Phillips, J. P., et al, Journal of Organic Chemistry, 1954, 907-9 *
Phillips, J. P., et al, Journal of Organic Chemistry, 1956, 692-4 *
Phillips, J. P., et al, Journal of the American Chemical Society, 1953, 75(17), 4306-7 *
Robisch, G., et al, Journal f. prakt. Chemie, 1985, 871-77 *
Roxas-Duncan, V., et al, Antimicrobial Agents and Chemotherapy, 2009, 53(8), 3478-86 *
Smirnova, N. A., et al, Chemistry and Biology, 2010, 17, 380-91 *
Tomlinson, M. L., et al, Chemistry and Biology, 2009, 16(1), 93-104 *

Also Published As

Publication number Publication date
HUE050886T2 (hu) 2021-01-28
CA2798419A1 (en) 2011-12-01
MX2012012883A (es) 2013-03-20
SMT201900710T1 (it) 2020-01-14
PT2566849T (pt) 2020-01-06
CN102985407B (zh) 2015-09-09
HRP20192278T1 (hr) 2020-03-06
RS59678B1 (sr) 2020-01-31
PL2566849T3 (pl) 2020-03-31
HUP1000243A2 (en) 2012-01-30
JP5812541B2 (ja) 2015-11-17
EA021026B1 (ru) 2015-03-31
KR20130029772A (ko) 2013-03-25
HU1000243D0 (en) 2010-06-28
ES2761832T3 (es) 2020-05-21
US8871937B2 (en) 2014-10-28
DK2566849T3 (da) 2020-01-02
NZ603967A (en) 2014-06-27
EA201270787A1 (ru) 2013-04-30
KR101837974B1 (ko) 2018-03-13
SI2566849T1 (sl) 2020-02-28
EP2566849A1 (en) 2013-03-13
JP2013525473A (ja) 2013-06-20
MX337999B (es) 2016-03-30
CN102985407A (zh) 2013-03-20
EP2566849B1 (en) 2019-09-18
US20130131096A1 (en) 2013-05-23
CY1122426T1 (el) 2021-01-27
CA2798419C (en) 2021-01-05
AU2011256989A1 (en) 2013-01-10
WO2011148208A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
Liu et al. Novel coumarin-thiazolyl ester derivatives as potential DNA gyrase Inhibitors: Design, synthesis, and antibacterial activity
JP5635396B2 (ja) 抗がん活性を有する化合物
JP5001650B2 (ja) ベンズイミダゾールカルボキサミド
JP5670266B2 (ja) フラザノベンゾイミダゾール
CA2539707C (en) Quinoline potassium channel inhibitors
CN108524482B (zh) 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
CA2857405A1 (en) Phthalic hydrazide (phthalazine ketone) compounds as parp inhibitors and composition thereof
KR20170095964A (ko) Hdac1/2 억제제로서 피페리딘 유도체
CA2798419C (en) 8-hydroxy-quinoline derivatives
JP2015535265A (ja) 新たなキノリン類の化合物及びその使用
JPWO2016148114A1 (ja) 酸化ストレス誘導神経細胞死抑制化合物
JP2007517787A (ja) アロイルフランおよびアロイルチオフェン
JP4794445B2 (ja) キノリンカリウムチャネル阻害剤
AU2009248231A1 (en) Novel N-(2-amino-phenyl)-acrylamides
AU2017341020B2 (en) Urea derivative
US9381260B2 (en) Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
WO2015074124A1 (en) Functionalised and substituted indoles as anti-cancer agents
KR20240057820A (ko) 신규 피라졸로-옥소티아졸리딘 유도체 및 이를 포함하는 알칼리성 포스파타제 억제제
CN119118928A (zh) 作为脯氨酰羟化酶抑制剂的噌啉类化合物
CN117486813A (zh) N-二取代苯基丙烯酰胺类化合物及其药物组合物和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired